The move by Eli Lilly came less than 24 hours after Johnson & Johnson paused further dosing in all of its COVID-19 vaccine candidate clinical trials while it investigated a volunteer's illness.
The company had placed its worldwide vaccine trials on hold for several days. It now says a safety review by regulators and reviewers is complete. No word on when studies in the U.S. might resume.